Fluoxetine

Modify Date: 2024-01-02 17:11:26

Fluoxetine structure	Common Name	Fluoxetine
	CAS Number	54910-89-3	Molecular Weight	309.326
	Density	1.2±0.1 g/cm3	Boiling Point	395.1±42.0 °C at 760 mmHg
	Molecular Formula	C₁₇H₁₈F₃NO	Melting Point	158ºC
	MSDS	N/A	Flash Point	192.8±27.9 °C

Use of Fluoxetine

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

Name	Fluoxetine
Synonym	More Synonyms

Description	Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Neuronal Signaling >> Serotonin Transporter Research Areas >> Neurological Disease
In Vitro	Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell[1]. Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex[2]. Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus[3]. Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration[4].
In Vivo	Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague-Dawley rats[1]. Fluoxetine (5 mg/kg) alone increases cell proliferation in the dentate gyrus. Coadministration (fluoxetine 5 mg/kg + olanzapine) also significantly increases the number of BrdU-positive cells compared with the control group[2]. Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone[5].
Animal Admin	Male Sprague-Dawley rats weighing 250-300 g are housed under a 12-hour light/12-hour dark cycle (lights on at 7:00 am, lights off at 7:00 pm) and at constant temperature (25°C) and humidity and allowed free access to food and water. For chronic drug treatments, rats are administered fluoxetine (5 mg/kg/day) or saline by intraperitoneal (IP) injection once daily and olanzapine or vehicle in the drinking water for 21 days (vehicle-treated control, fluoxetine, and olanzapine alone) plus the combination of fluoxetine and olanzapine. For combination treatment, olanzapine is chosen because fluoxetine is known to interfere with the metabolism of olanzapine and raise the blood levels by up to 4-6 times. Olanzapine is dissolved in hydrochloric acid (HCl), then adjusted back to pH 6 with 1 N sodium hydroxide to make the stock solution of 3 mg/mL concentration. The same amount of vehicle solution is added to the water for the control animals. Fluid intake is measured three times per week, and drinking bottles are replenwashed with fresh drug solution. There are no differences in fluid intake among the treatment groups. For subchronic treatment, drugs are administered exactly the same way but for a total period of 7 days.
References	[1]. Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71 [2]. Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80. [3]. Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84. [4]. Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61 [5]. Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62. [6]. Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? Behav Brain Res. 2017 Jan 15;317:62-70.

Density	1.2±0.1 g/cm3
Boiling Point	395.1±42.0 °C at 760 mmHg
Melting Point	158ºC
Molecular Formula	C₁₇H₁₈F₃NO
Molecular Weight	309.326
Flash Point	192.8±27.9 °C
Exact Mass	309.134064
PSA	21.26000
LogP	4.09
Vapour Pressure	0.0±0.9 mmHg at 25°C
Index of Refraction	1.511

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DA8326855

CHEMICAL NAME :: Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-

CAS REGISTRY NUMBER :: 54910-89-3

LAST UPDATED :: 199801

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C17-H18-F3-N-O

MOLECULAR WEIGHT :: 309.36

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 60 mg/kg/21W-I

TOXIC EFFECTS :: Nutritional and Gross Metabolic - other changes

REFERENCE :: AJPSAO American Journal of Psychiatry. (American Psychiatric Assoc., Circulation Dept., 1400 K St., NW, Washington, DC 20005) V.78- 1921- Volume(issue)/page/year: 153,134,1996

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 72 mg/kg/26W-I

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity)

REFERENCE :: JCPYDR Journal of Clinical Pyschopharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1981- Volume(issue)/page/year: 10,343,1990

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 16800 ug/kg/6W-I

TOXIC EFFECTS :: Behavioral - muscle weakness Behavioral - antipsychotic Nutritional and Gross Metabolic - other changes

REFERENCE :: AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 156,681,1996

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 2 mg/kg/5D-I

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - other changes

REFERENCE :: AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 156,681,1996

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 825 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 121 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 464 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 87500 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 15,1178,1990 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 80 mg/kg

SEX/DURATION :: female 13-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - biochemical and metabolic

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 280,138,1997

Hazard Codes	C,Xi
Risk Phrases	R34:Causes burns. R36/37:Irritating to eyes and respiratory system . R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases	S23-S26-S27-S36/37/39-S45-S37/39
RIDADR	UN 3265 8/PG 2
WGK Germany	2
Packaging Group	III
Hazard Class	8
HS Code	29036990

Precursor 9
CAS#:42142-52-9 3-Hydroxy-N-met... CAS#:98-56-6 4-Chlorobenzotr... CAS#:204704-95-0 Ethyl N-methyl-... CAS#:402-45-9 4-Trifluorometh...
CAS#:57226-06-9 methyl-[3-pheny... CAS#:936-59-4 3-Chloropropiop... CAS#:56296-78-7 Fluoxetine Hydr... CAS#:18776-12-0 3-Chloro-1-phen...
CAS#:62872-58-6 3-iodo-1-phenyl...
DownStream 2
CAS#:56296-78-7 Fluoxetine Hydr... CAS#:114247-09-5 R-Fluoxetine hy...

HS Code	29036990

Adofen

MFCD00072041

AURORA KA-7692

Reneuron

Fluctin

Foxetin

Fluoxeren

Fluval

fluoxetina

EINECS 611-209-7

Henan Tianfu Chemical Co., Ltd.
China
Product Name: Fluoxetine
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson

Get all suppliers and price by the below link:

Fluoxetine suppliers

Price: $72/50mg

Reference only. check more Fluoxetine price